For people with allergies, ongoing exposure to triggers may create a cycle of inflammation that contributes to polyp ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Amgen (AMGN) and AstraZeneca's (AZN) asthma therapy Tezspire hits main goals in the Phase 3 trial for chronic rhinosinusitis ...

Last month, GSK reported that its highly touted investigational asthma treatment depemokimab reduced nasal polyps in two ...

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...

Nasal polyps are small noncancerous growths in the nose or sinuses. They may cause pain or pressure in the face, runny or stuffy nose, and other symptoms or complications that may negatively ...

A study published in Frontiers in Medicine reveals that chronic rhinosinusitis with and without nasal polyps is closely correlated with asthma.A study was done to investigate the ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

The co-primary endpoints were change from baseline in total nasal polyp size (measured by endoscopic total Nasal ... name Tezspire ® for the add-on maintenance treatment of severe asthma in adult and ...

Researchers recently identified five extrapulmonary treatable traits in asthma that are clinically relevant and have a clear diagnostic process.

IL-5 is present at high levels in nasal polyp tissue. IL-5 inhibitors play ... 2 — which evaluated depemokimab for treating severe asthma characterized by type II inflammation met their primary ...

Nucala is approved for four indications, namely severe eosinophilic asthma CRSwNP ... of a key inflammatory pathway underlying nasal polyp growth and nasal obstruction," he added.